The present invention provides methods and compositions for the prophylactic or targeted prophylactic treatment of migraine. In one embodiment a patient is regularly given a therapeutically effective amount of a combination of a cyclooxygenase-2 inhibitor and acetylsalicylic acid or active derivative, for prophylactic treatment of migraine. In another embodiment, a patient, at a time prior to a determined time window, is administered a therapeutically effective amount of a cyclooxygenase-2 inhib...

An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile followin...

The present invention provides a process for preparing orlistat from amino orlistat using Pivaloyl Formic Anhydride (PFA) as an alkanoylating agent.

The present invention relates to microalgae having high efficiency and ability to remove carbon dioxide and the use thereof. More specifically the invention relates to Scenedesmus producto-capitatus microalgae having high carbon dioxide fixation rate and the use thereof. The microalgae of the invention have a high carbon dioxide fixation rate and excellent resistance even to high concentrations of carbon dioxide sulfur oxide (SOx) and nitric oxide (NOx) and are rich in biomass and thus can be ad...

A preparation process of esomeprazole sodium substantially free of sulfone impurity including the steps of: a) combining either esomeprazole with a (C3-C8)-ketone or a mixture thereof a sodium alkoxide and a (C1-C5)-alcohol or esomeprazole sodium with a (C3-C8)-ketone or a mixture thereof and a (C1-C5)-alcohol; and b) recovering the esomeprazole sodium formed from the reaction media by filtration.

Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 12-ethanediol oligo- or polymers and a pyrrolidone solvent.

The present invention features interferon-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example the therapies comprise administering to the subject effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic agent 3) an inhibitor of cytochrome P450 (e.g. rito...